If FCR may be the treatment of decision, warning has to be taken in patients with NOTCH1 mutations, in whom rituximab appears to have very little included value.59 Other genomic subgroups, such as sufferers with BIRC3 mutations seem to derive very little get pleasure from CIT,111,112 but these outco